On the afternoon of May 25th, the results of the Phase III clinical trial (GLORY-1) of marsteglutide, the world’s first glucagon (GCG)/glucagon-like peptide-1 (GLP-1) dual receptor agonist to apply for marketing, in Chinese subjects with overweight or obesity, led by Professor Ji Linong’s team from Peking University People’s Hospital (PKUPH), were published online in full text in the international top medical journal The New England Journal of Medicine ( NEJM ). In the same issue, NEJM published an editorial titled “Overweight and Obesity — Taking Control of the Whole Picture”, which highly affirmed the comprehensiveness of the drug’s evaluation of obesity-related efficacy indicators in the marsteglutide clinical trial and prospected the clinical application of the drug.

　　This marks the first time that innovative drug clinical research achievements in the field of endocrine and metabolic diseases in China have been published in this international authoritative journal. It is also the first paper published by PKUPH in this journal in the form of a research article (article), marking that China’s drug R&D level in metabolic diseases has reached a new level and reflecting the outstanding strength of Chinese medical researchers.

　　Written by: Wu Zhaoxia

　　Edited by: LiuXin

　　Source: Peking University People’s Hospital